Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open, Multicenter Phase II Clinical Study of Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

NCT06374888 is registered in ClinicalTrials.gov with Convalife (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06374888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06374888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open, Multicenter Phase II Clinical Study of Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Lead sponsor
Convalife (Shanghai) Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2024
Completion date
July 30, 2027
Enrollment
28 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastasis